Please try another search
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Changseuk Hwang | - | - | Director |
Soon-Ro Cho | - | - | Director |
Phillippe Shin | - | - | Director |
Jinhwa Lee | - | - | Director |
Ki-Yean Nam | 51 | - | CEO, CSO & Chairman |
Sei-hun An | - | - | Director |
Jaesung No | - | - | Director |
Joongsik Hwang | - | - | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review